De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits
S. Ng, Y.-C. Juang, A. Chandramohan, H. Y. K. Kaan, A. Sadruddin, T. Y. Yuen, F. J. Ferrer, X. E. C. Lee, L. Xi, C. W. Johannes, C. J. Brown, S. Kannan, P. G. Aronica, N. Berglund, C. S. Verma, , D. P. Lane
This paper identifies false-positive peptide inhibitors of KRas using orthogonal assays and cellular screens, highlighting the need for rigorous validation in drug discovery.
bioRxiv · May 21, 2019Biochemistry